Insulet Corp
Uždarymo kaina
SektoriusSveikatos priežiūra
147.63 -0.13
Apžvalga
Akcijų kainos pasikeitimas
24 val.
Min
146.07
Max
149.3
Pajamos | -11M 91M |
|---|---|
Pardavimai | -22M 762M |
P/E Sektoriaus vid. | 35.482 49.052 |
Pelnas, tenkantis vienai akcijai | 1.3 |
Pelno marža | 11.96 |
Darbuotojai | 5,400 |
EBITDA | -23M 154M |
Rekomendacijos | Stiprus pirkimas |
|---|---|
12 mėnesių prognozė | +54.82% upside |
Kitas uždarbis | 2026-08-06 |
|---|
Rinkos kapitalizacija | -1.4B 10B |
|---|---|
Ankstesnė atidarymo kaina | 147.76 |
Ankstesnė uždarymo kaina | 147.63 |
Naujienos nuotaikos
By Acuity
68%
32%
309 / 342 reitingas Healthcare
Insulet Corp Grafikas
Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.
Apie bendrovę Insulet Corp
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.